Bluejay Diagnostics Inc. (NASDAQ: BJDX) announced a strategic partnership with Argonaut Manufacturing Services to support the advancement of its Symphony platform for near-patient testing in critical care settings.

The collaboration aims to establish scalable U.S.-based manufacturing capabilities for Bluejay's diagnostic platform. The partnership is intended to support the company's clinical development programs and future commercialization objectives while reducing reliance on overseas manufacturing.

The agreement focuses on strengthening Bluejay's commercial infrastructure by supporting product distribution across the United States, enhancing supply chain resilience, and reducing risks associated with international sourcing and import tariffs. The domestic manufacturing capabilities are designed to provide greater operational control and supply chain security.

"We are pleased to partner with Argonaut as we continue to advance the Symphony platform," said Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics. "This collaboration reflects our commitment to building a scalable and quality-focused operational foundation as we progress toward key commercial milestones."

Rick Hancock, Chief Executive Officer of Argonaut Manufacturing Services, stated that the company is "committed to partnering with innovative companies to support the advancement of differentiated diagnostic technologies."

Bluejay's Symphony System is designed for sepsis triage and monitoring disease progression. The company's IL-6 test is intended to provide results in approximately 20 minutes. The Symphony System does not yet have regulatory clearance and requires authorization from the U.S. Food and Drug Administration before it can be marketed as a diagnostic product in the United States.

Argonaut Manufacturing Services is a contract manufacturing organization founded by former executives from companies including Thermo Fisher Scientific, Affymetrix, and Allergan.